Albumin conjugated with WQPDTAHHWATL and GRFLTGGTGRLLRIS peptide improves targeted docetaxel delivery for prostate cancer: an in-silico approach

Karim Mahnam , Zeinab Karami, Yaser Salehi Najafabadi

Abstract


Background and purpose: Prostate cancer is one of the most common cancers in the world. Anti-prostate cancer drugs such as docetaxel, doxorubicin, and cabazitaxel have drawbacks resulting from their low solubility, non-targeted transfer, and many side effects. Prostate-specific membrane antigen (PSMA) receptor is expressed on the surface of prostate cancer cells. It was known that “WQPDTAHHWATL” and “GRFLTGGTGRLLRIS” peptides tended to bind this receptor.

Theoretical approach: “WQPDTAHHWATL” and “GRFLTGGTGRLLRIS” peptides were attached to the C and N tails of albumin protein, and an engineered albumin was designed. Then, engineered albumin and the extracellular domain of PSMA were separately simulated for 100 ns. Afterward, the interaction of engineered albumin with anti-prostate cancer drugs and the PSMA domain was investigated independently by molecular docking, molecular dynamics simulation, and molecular mechanics energies/Poisson-Boltzmann surface area binding free energy methods.

Findings/Results: The binding affinity order of drugs to engineered albumin was docetaxel, doxorubicin, and cabazitaxel, respectively. Also, the residence time of docetaxel was longer than that of other drugs. The final picture of complexes showed that cabazitaxel and docetaxel bound to site IB, and doxorubicin bound to site IIA of the recombinant albumin. Additionally, the C-terminus and N-terminus of the engineered albumin could bind to the PSMA receptor.

Conclusion and implications: It can be concluded that this engineered albumin is useful for targeted drug delivery in prostate cancer.

 

 


Keywords


Albumin; Molecular dynamics simulation; Prostate-specific membrane receptor; Protein docking; Residence time; Targeted drug delivery.

Full Text:

PDF

References


Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89.DOI: 10.14740/wjon1191.

Paal K, Shkarupin A, Beckford L. Paclitaxel binding to human serum albumin-automated docking studies. Bioorg Med Chem. 2007;15(3):1323-1329.DOI: 10.1016/j. bmc.2006.11.012.

Carbonetti G, Converso C, Clement T, Wang C, Trotman LC, Ojima I, et al. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth. Prostate. 2020;80(1):88-98.DOI: 10.1002/pros.23921.

Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023;14:1157306,1-14.DOI: 10.3389/fphar.2023.1157306.

Vigevani A, Williamson MJ. Doxorubicin. In: Klaus Florey, Editor. Analytical profiles of drug substances. Vol 9. New York: Academic Press; 1981. pp. 245-274.

Khoeeniha MK, Esfandyari-Manesh M, Behrouz H, Amini M, Shiri Varnamkhasti B, Atyabi F., et al. Targeted delivery of cabazitaxel by conjugation to albumin-PEG-folate nanoparticles using a cysteine-acrylate linker and simple synthesis conditions. Curr Drug Deliv. 2017;14(8):1120-1129.DOI: 10.2174/1567201814666161122150302.

Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochym Biophys Acta. 2013;1830(12):5526-5534.DOI: 10.1016/j.bbagen.2013.04.023.

Spada A, Emami J, Tuszynski JA, Lavasanifar A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol Pharmaceutics. 2021;18(5):1862-1894.DOI: 10.1021/acs. molpharmaceut.1c00046.

Nezir AE, Khalily MP, Gulyuz S, Ozcubukcu S, Küçükgüzel SG, Yilmaz O, et al. Synthesis and evaluation of tumor‑homing peptides for targeting prostate cancer. Amino Acids. 2021;53(5):645-652.DOI: 10.1007/s00726-021-02971-3.

Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528-539.DOI: 10.1002/jcb.10661.

Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 2006;66(18):9171-9177.DOI: 10.1158/0008-5472.CAN-06-1520.

Van de Sande L, Cosyns S, Willaert W, Ceelen W. Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review. Drug Deliv. 2020;27(1):40-53.DOI: 10.1080/ 10717544.2019.1704945.

Carter DC. Crystallographic survey of albumin drug interaction and preliminary applications in cancer chemotherapy. In: Abraham DJ, Rotella DP, Editors. Burger’s medicinal chemistry, drug discovery, and development. 7th ed. Hoboken: John Wiley & Sons Inc; 2010. pp: 437-468.DOI: 10.1002/0471266949.bmc166.

Rahimizadeh P, Yang S, Lim SI. Albumin: an emerging opportunity in drug delivery. Biotechnol Bioprocess Eng. 2020;25:985-995.DOI: 10.1007/s12257-019-0512-9.

Challapa-Mamani MR, Tomás-Alvarado E, Espinoza-Baigorria A, León-Figueroa DA, Sah R, Rodriguez-Morales AJ, et al. Molecular docking and molecular dynamics simulations in related to Leishmania donovani: an update and literature review. Trop Med Infect Dis. 2023;8(10):457,1-13.DOI: 10.3390/tropicalmed8100457.

Elsadek B, Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J Control Release. 2012;157(1):4-28.DOI: 10.1016/j.jconrel.2011.09.069.

Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183.DOI: 10.1016/j.jconrel.2008.05.010.

Qu N, Sun Y, Li Y, Hao F, Qiu P, Teng L, et al. Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation. Biomed Eng Online. 2019;18(1):11,1-14.DOI: 10.1186/s12938-019-0624-7.

Su Z, Zhao J, Zhao X, Xie J, Li M, Zhao D. Preclinical evaluation of albumin-bound docetaxel nanoparticles as potential anti-cancer products. Int J Pharm. 2023;635:122711.DIO: 10.1016/j.ijpharm.2023.122711.

Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Invest New Drugs. 1996;14(2):147-151.DOI: 10.1007/BF00210785.

Qi WW, Yu HY, Guo H, Lou J, Wang ZM, Liu P, et al. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Mol Pharmaceutics. 2015;12(3):675-683.DOI: 10.1021/mp500394v.

Di Stefano G, Fiume L, Baglioni M, Bolondi L, Chieco P, Kratz F, et al. Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. Dig Liver Dis. 2008;40(4):278-284.DOI: 10.1016/j.dld.2007.10.008.

Maltas E, Gubbuk IH, Yildiz S. Development of doxorubicin loading platform-based albumin-sporopollenin as drug carrier. Biochem Biophys Rep. 2016;7:201-205.DOI: 10.1016/j.bbrep. 2016.06.012.

Agudelo D, Bourassa P, Bruneau J, Bérubé, G, Asselin É, Tajmir-Riahi HA. Probing the binding sites of antibiotic drugs doxorubicin and N-(trifluoroacetyl) doxorubicin with human and bovine serum albumins. PLoS One. 2012;7(8):e43814,1-13.DOI: 10.1371/journal.pone.0043814.

Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 2016;4(3):1-12.DOI: 10.1186/s40591-016-0048-8.

Wacker M. Nanocarrier for intravenous injection- long hard road to market. Int J Pharm. 2013:457(1):50-62.DOI: 10.1016/j.ijpharm.2013.08.079.

Rezaei L, Safavi MS, Shojaosadati SB. Protein nanocarriers for targeted drug delivery. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S, Editors. Characterization and biology of nanomaterials for drug delivery: nanoscience and nanotechnology in drug delivery. Amsterdam: Elsevier Science Publishing Co. Inc. 2018.DOI: 10.1016/B978-0-12-814031-4.00008-8.

Barkhordari A, Mahnam K, Mirmohammad-Sadeghi H. Designing a new bispecific tandem single-chain variable fragment antibody against tumor necrosis factor-α and interleukin-23 using in silico studies for the treatment of rheumatoid arthritis. J Mol Model. 2020;26(9):225,1-11.DOI: 10.1007/s00894-020-04510-5.

Mohammadian H, Mahnam K, Mirmohammad Sadeghi H, Ganjalikhany MR, Akbari V. Rational design of a new mutant of tobacco etch virus protease in order to increase the in vitro solubility. Res Pharm Sci. 2020;15(2):164-173.DOI: 10.4103/1735-5362.273816.

Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1(2):19-25.DOI: 10.1016/j.softx.2015.06.001.

Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639-1662.DOI: 10.1002/(SICI)1096-987X(19981115)19:14< 1639::AID-JCC10>3.0.CO;2-B.

Santos-Martins D, Eberhardt J, Bianco G, Solis-Vasquez L, Ambrosio FA, Koch A, et al. D3R Grand Challenge 4: prospective pose prediction of BACE1 ligands with AutoDock-GPU. J Comput Aided Mol Des. 2019;33(12):1071-1081.DOI: 10.1007/s10822-019-00241-9.

Chen X, Zaro J, Shen WC. Fusion protein linkers: property, design, and functionality. Adv Drug Deliv Rev. 2013;65(10):1357-1369.DOI: 10.1016/j.addr.2012.09.039.

Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 2001;14(8):529-532.DOI: 10.1093/protein/14.8.529.

Amet N, Lee HF, Shen WC. Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharm Res. 2009;26(3): 523-528.DOI: 10.1007/s11095-008-9767-0.

Bai Y, Shen WC. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm Res. 2006;23:2116-2121.DOI: 10.1007/s11095-006-9059-5.

Drozdetskiy A, Cole C, Procter J, Barton GJ. JPred4: a protein secondary structure prediction server. Nucleic Acids Res. 2015;43(W1):W389-W394.DOI: 10.1093/nar/gkv332.

Mahnam K, Rajaee SM. A theoretical survey to find potential natural compound for inhibition of binding the RBD domain to ACE2 receptor based on plant antivirals. J Biomol Struct Dyn. 2023;41(23):14540-14565.DOI: 10.1080/07391102. 2023.2183033.

Kumari R, Kumar R, Open Source Drug Discovery Consortium, Lynn A. g_mmpbsa, a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014;54(7):1951-1962‏.DOI: 10.1021/ci500020m.

Dominguez C, Boelens R, Bonvin AMJJ. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc. 2003;125(7):1731-1737.DOI: 10.1021/ja026939x.

Kokh DB, Amaral M, Bomke J, Grädler U, Musil D, Buchstaller HP, et al. Estimation of drug-target residence times by τ-random acceleration molecular dynamics simulations. J Chem Theory Comput. 2018;14(7):1549-9618.DOI: 10.1021/acs.jctc.8b00230.

Lüdemann SK, Lounnas V, Wade RC. How do substrates enter and products exit the buried active site of cytochrome P450cam? 2. steered molecular dynamics and adiabatic mapping of substrate pathways. J Mol Biol. 2000;303(5):813-830.DOI: 10.1006/jmbi.2000.4155.

Duarte JM, Sathyapriya R, Stehr H. Filippis I, Lappe M. Optimal contact definition for reconstruction of Contact Maps. BMC Bioinformatics. 2010;11(283):7761,1-10.DOI: 10.1186/1471-2105-11-283.

Sang P, Du X, Yang LQ, Meng ZH, Liu SQ. Molecular motions and free-energy landscape of serine proteinase K in relation to its cold-adaptation: a comparative molecular dynamics simulation study and the underlying mechanisms. RSC Adv. 2017;7(46):28580-28590.DOI: 10.1039/c6ra23230b.

Amadei A, Linssen ABM, Berendsen HJC. Essential dynamics of proteins. Proteins. 1993;17(4):412-425.DOI: 10.1002/prot.340170408.

Maisuradze GG, Liwo A, Scheraga HA. How adequate are one- and two-dimensional free energy landscapes for protein folding dynamics? Phys Rev Lett. 2009;102:238102,1-8.DOI: 10.1103/PhysRevLett.102.238102.

Bai F, Xu Y, Chen J, Liu Q, Gu J, Wang X, et al. Free energy landscape for the binding process of Huperzine A to acetylcholinesterase. Proc Natl Acad Sci. 2013;110(11):4273-4278.DOI: 10.1073/pnas.1301814110.

Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8(2):127-134.DOI:10.1093/protein/ 8.2.127.

Lozano-Aguilera ED, Estudillo-Martínez MD, Castillo-Gutiérrez S. A proposal for plotting positions in probability plots. J Appl Stat. 2014;41(1):118-126.DOI: 10.1080/02664763.2013.831814.

Mohammadi pour P, Mahnam K, Taherzadeh M, Ahangarzadeh S, Alibakhshi A, Mohammadi E. The effect of mutation on neurotoxicity reduction of new chimeric reteplase, a computational study. Res Pharm Sci. 2023;18(4):404-412.DOI: 10.4103/1735-5362.378087.

Jenik M, Parra RG, Leandro GR, Radusky LG, Turjanski A, Peter G, et al. Protein frustratometer: a tool to localize energetic frustration in protein molecules. Nucleic Acids Res. 2012;40(W1):W348-W351.DOI: 10.1093/nar/gks447.

Parra RG, Schafer NP, Radusky LG, Tsai MY, Guzovsky AB, Wolynes PG, et al. Protein Frustratometer 2: a tool to localize energetic frustration in protein molecules, now with electrostatics. Nucleic Acids Res. 2016;44(W1):W356-W360.DOI: 10.1093/nar/gkw304.

Amir M, Ahmad S, Ahamad S, Kumar V, Mohammad T, Dohare R, et al. Impact of Gln94Glu mutation on the structure and function of protection of telomere 1, a cause of cutaneous familial melanoma. J Biomol Struct Dyn. 2020;38(5):1514-1524.DOI:10.1080/07391102.2019.1610500.

Pal S, Reshma G B, Mohny FP, Choudhury SG, Karmakar A, Gupta S, et al. Albumin nanoparticles surface decorated with a tumor-homing peptide help in selective killing of triple-negative breast cancer cells. ACS Appl Mater Interfaces. 2023;15(40):46721-46737.DOI: 10.1021/acsami.3c11561.

Sasidharan S, Radhakrishnan K, Lee JY, Saudagar P, Gosu V, Shin D. Molecular dynamics ERRγ ligand binding domain with agonist and inverse agonist. PLoS One.2023;18(4):e0283364,1-18.DOI: 10.1371/journal.pone.0283364.

Karami L, Tazikeh-Lemeskib E, Saboury AA. Molecular dynamics simulation and free energy studies on the interaction of salicylic acid with human serum albumin (HSA). Phys Chem Res. 2017;5(3):483-496.DOI: 10.22036/pcr.2017.63757.1315.

Deshpande SH, Bagewadi ZK, Khan TMY, Mahnashi MH, Shaikh IA, Alshehery S, et al. Exploring the potential of phytocompounds for targeting epigenetic mechanisms in rheumatoid arthritis: an in silico study using similarity indexing. Molecules. 2023;28:2430,1-13.DOI: 10.3390/molecules28062430.

Voss JH, Crüsemann M, Bartling CRO, Kehraus S, Inoue A, Gabriele M, et al. Structure-affinity and structure-residence time relationships of macrocyclic Gαq protein inhibitors. iScience. 2023;26(4):106492,1-19.DOI: 10.1016/j.isci.2023.106492.

Tafech A, Stéphanou A. On the importance of acidity in cancer cells and therapy. Biology. 2024;13(4):225,1-25.DOI: 10.3390/biology13040225.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.